LMBA02 Protocol for Patients With a Burkitt Lymphoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To explore in a multicenter international prospective randomized study (phase III) whether
rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate
of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt
lymphoma or ALL 3.